Variations in committed stem cells (CFU-GM and CFU-TL) in the peripheral blood of cancer patients treated by sequential combination chemotherapy for breast cancer
- PMID: 6713410
Variations in committed stem cells (CFU-GM and CFU-TL) in the peripheral blood of cancer patients treated by sequential combination chemotherapy for breast cancer
Abstract
The present work compared the blood variations in some committed stem cells (CSC), and corresponding differentiated WBC during the first three courses of a 6-day sequential chemotherapy given to 16 breast cancer patients for 28 days each. The granulomonocytic and lymphocytic colony-forming unit levels in blood were significantly lowered in cancer patients before treatment. These CSC appeared to have cyclic variations following each course of chemotherapy. In granulomonocytic colony-forming units, a nadir was observed by Day 15, followed by a sharp rebound above the initial values by Days 22 to 24, which was not affected in magnitude by the continuation of treatment. In lymphocytic colony-forming units, the Day 1 level increased with the continuation of chemotherapy. The initial decrease was less marked, but by Day 15 a minimal level was also observed, followed by a progressive increase to reach a maximum by Day 28. Leukocytes and granulocytes reached a nadir by Days 16 to 17 and recovered by Day 25. The cyclic evolution of monocytes was less apparent as was that of lymphocytes; however, there was less restoration of monocytes and lymphocytes than of granulocytes at the end of the resting period. This study showed: (a) an apparent relationship between the level of CSC in blood, and subsequent variations in the corresponding mature cells of the same lineage; and (b) a weak interval of time between the nadir and peaks of CSC and the corresponding mature cells, which was more evident in the granulocytic lineage. These observations seemed to be of physiological importance, but the possible prediction value of peripheral granulomonocytic colony-forming unit peak magnitude following treatment remains to be established.
Similar articles
-
Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.Bone Marrow Transplant. 1998 Jan;21(2):123-6. doi: 10.1038/sj.bmt.1701058. Bone Marrow Transplant. 1998. PMID: 9489627 Clinical Trial.
-
The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.Anticancer Res. 1995 Nov-Dec;15(6B):2851-6. Anticancer Res. 1995. PMID: 8669878
-
Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.Bone Marrow Transplant. 1999 Nov;24(9):971-9. doi: 10.1038/sj.bmt.1702008. Bone Marrow Transplant. 1999. PMID: 10556956 Clinical Trial.
-
Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.Bone Marrow Transplant. 1993 Apr;11(4):271-7. Bone Marrow Transplant. 1993. PMID: 7683551
-
A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.Exp Hematol. 1996 Jun;24(7):823-8. Exp Hematol. 1996. PMID: 8647233 Clinical Trial.
Cited by
-
G-CSF and GM-CSF in clinical trials.Yale J Biol Med. 1990 Sep-Oct;63(5):387-410. Yale J Biol Med. 1990. PMID: 1705737 Free PMC article. Review.
-
GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.Breast Cancer Res Treat. 1991 Dec;20 Suppl:S25-9. doi: 10.1007/BF01908241. Breast Cancer Res Treat. 1991. PMID: 1687204
MeSH terms
Substances
LinkOut - more resources
Medical